Search Results - "CALLAHAN, Margaret K"

Immune Checkpoint Blockade in Cancer Therapy by Postow, Michael A, Callahan, Margaret K, Wolchok, Jedd D

“…Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1…”
Get full text

Targeting T Cell Co-receptors for Cancer Therapy by Callahan, Margaret K., Postow, Michael A., Wolchok, Jedd D.

“…Checkpoint-blocking antibodies can generate potent anti-tumor responses by encouraging the immune system to seek and destroy cancer cells. At this time, the…”
Get full text

At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy by Callahan, Margaret K., Wolchok, Jedd D.

“…Clinical Review for Basic Researchers: Treating patients with CTLA‐4 and PD‐1 pathway blocking antibodies, plus clinical progress and application of agents in…”
Get full text

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis by Dubin, Krista, Callahan, Margaret K., Ren, Boyu, Khanin, Raya, Viale, Agnes, Ling, Lilan, No, Daniel, Gobourne, Asia, Littmann, Eric, Huttenhower, Curtis, Pamer, Eric G., Wolchok, Jedd D.

“…The composition of the intestinal microbiota influences the development of inflammatory disorders. However, associating inflammatory diseases with specific…”
Get full text

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody by Iwama, Shintaro, De Remigis, Alessandra, Callahan, Margaret K, Slovin, Susan F, Wolchok, Jedd D, Caturegli, Patrizio

“…Hypophysitis is a chronic inflammation of the pituitary gland of unknown (primary forms) or recognizable (secondary forms) etiology, such as the use of…”
Get more information

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial by Sharma, Padmanee, Prof, Callahan, Margaret K, MD, Bono, Petri, MD, Kim, Joseph, MD, Spiliopoulou, Pavlina, MD, Calvo, Emiliano, MD, Pillai, Rathi N, MD, Ott, Patrick A, MD, de Braud, Filippo, Prof, Morse, Michael, Prof, Le, Dung T, MD, Jaeger, Dirk, MD, Chan, Emily, MD, Harbison, Chris, PhD, Lin, Chen-Sheng, PhD, Tschaika, Marina, MD, Azrilevich, Alex, PharmD, Rosenberg, Jonathan E, MD

“…Summary Background Few effective treatments exist for patients with advanced urothelial carcinoma that has progressed after platinum-based chemotherapy. We…”
Get full text

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers by Teo, Min Yuen, Seier, Kenneth, Ostrovnaya, Irina, Regazzi, Ashley M, Kania, Brooke E, Moran, Meredith M, Cipolla, Catharine K, Bluth, Mark J, Chaim, Joshua, Al-Ahmadie, Hikmat, Snyder, Alexandra, Carlo, Maria I, Solit, David B, Berger, Michael F, Funt, Samuel, Wolchok, Jedd D, Iyer, Gopa, Bajorin, Dean F, Callahan, Margaret K, Rosenberg, Jonathan E

“…Purpose Alterations in DNA damage response and repair (DDR) genes are associated with increased mutation load and improved clinical outcomes in…”
Get full text

Rational design of anti-GITR-based combination immunotherapy by Zappasodi, Roberta, Sirard, Cynthia, Li, Yanyun, Budhu, Sadna, Abu-Akeel, Mohsen, Liu, Cailian, Yang, Xia, Zhong, Hong, Newman, Walter, Qi, Jingjing, Wong, Phillip, Schaer, David, Koon, Henry, Velcheti, Vamsidhar, Hellmann, Matthew D., Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D., Merghoub, Taha

“…Modulating T cell homeostatic mechanisms with checkpoint blockade can efficiently promote endogenous anti-tumor T cell responses 1 – 11 . However, many…”
Get full text

Treatment Outcomes of Immune-Related Cutaneous Adverse Events by Phillips, Gregory S, Wu, Jennifer, Hellmann, Matthew D, Postow, Michael A, Rizvi, Naiyer A, Freites-Martinez, Azael, Chan, Donald, Dusza, Stephen, Motzer, Robert J, Rosenberg, Jonathan E, Callahan, Margaret K, Chapman, Paul B, Geskin, Larisa, Lopez, Adriana T, Reed, Vanessa A, Fabbrocini, Gabriella, Annunziata, Maria Carmela, Kukoyi, Oluwaseun, Pabani, Aliyah, Yang, Chih-Hsun, Chung, Wen-Hung, Markova, Alina, Lacouture, Mario E

“…The aim of the current study was to report the efficacy of topical and systemic treatments for immune-related cutaneous adverse events (ircAEs) attributed to…”
Get full text

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort by Ready, Neal E, Ott, Patrick A, Hellmann, Matthew D, Zugazagoitia, Jon, Hann, Christine L, de Braud, Filippo, Antonia, Scott J, Ascierto, Paolo A, Moreno, Victor, Atmaca, Akin, Salvagni, Stefania, Taylor, Matthew, Amin, Asim, Camidge, D Ross, Horn, Leora, Calvo, Emiliano, Li, Ang, Lin, Wen Hong, Callahan, Margaret K, Spigel, David R

“…Nivolumab monotherapy is approved in the United States for third-line or later metastatic small cell lung cancer based on pooled data from nonrandomized and…”
Get more information

Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas by Lito, Piro, Pratilas, Christine A., Joseph, Eric W., Tadi, Madhavi, Halilovic, Ensar, Zubrowski, Matthew, Huang, Alan, Wong, Wai Lin, Callahan, Margaret K., Merghoub, Taha, Wolchok, Jedd D., de Stanchina, Elisa, Chandarlapaty, Sarat, Poulikakos, Poulikos I., Fagin, James A., Rosen, Neal

“…BRAFV600E drives tumors by dysregulating ERK signaling. In these tumors, we show that high levels of ERK-dependent negative feedback potently suppress…”
Get full text

Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET by Peinado, Héctor, Alečković, Maša, Lavotshkin, Simon, Matei, Irina, Costa-Silva, Bruno, Moreno-Bueno, Gema, Hergueta-Redondo, Marta, Williams, Caitlin, García-Santos, Guillermo, Ghajar, Cyrus M, Nitadori-Hoshino, Ayuko, Hoffman, Caitlin, Badal, Karen, Garcia, Benjamin A, Callahan, Margaret K, Yuan, Jianda, Martins, Vilma R, Skog, Johan, Kaplan, Rosandra N, Brady, Mary S, Wolchok, Jedd D, Chapman, Paul B, Kang, Yibin, Bromberg, Jacqueline, Lyden, David

“…Exosomes can transfer proteins and nucleic acids from one cell to another, altering the phenotype of the recipient cell. In the case of cancer, tumor-derived…”
Get full text

Nivolumab plus Ipilimumab in Advanced Melanoma by WOLCHOK, Jedd D, KLUGER, Harriet, BURKE, Matthew M, CALDWELL, Anne, KRONENBERG, Stephanie A, AGUNWAMBA, Blessing U, XIAOLING ZHANG, LOWY, Israel, INZUNZA, Hector David, FEELY, William, HORAK, Christine E, QUAN HONG, CALLAHAN, Margaret K, KORMAN, Alan J, WIGGINTON, Jon M, GUPTA, Ashok, SZNOL, Mario, POSTOW, Michael A, RIZVI, Naiyer A, LESOKHIN, Alexander M, SEGAL, Neil H, ARIYAN, Charlotte E, GORDON, Ruth-Ann, REED, Kathleen

Get full text

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic by Callahan, Margaret K, Postow, Michael A, Wolchok, Jedd D

“…Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy. These…”
Get full text

Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy by Callahan, Margaret K, Wolchok, Jedd D, Allison, James P

“…Cytotoxic T-lymphocyte-associated antigen (CTLA-4), also known as CD152, is a co-inhibitory molecule that functions to regulate T-cell activation. Antibodies…”
Get full text

Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types by ASCIERTO, Paolo A, KALOS, Michael, SCHAER, David A, CALLAHAN, Margaret K, WOLCHOK, Jedd D

“…Modulation of the immune system by targeting coinhibitory and costimulatory receptors has become a promising new approach of immunotherapy for cancer. The…”
Get full text

Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis by Kuk, Deborah, Shoushtari, Alexander N., Barker, Christopher A., Panageas, Katherine S., Munhoz, Rodrigo R., Momtaz, Parisa, Ariyan, Charlotte E., Brady, Mary Sue, Coit, Daniel G., Bogatch, Kita, Callahan, Margaret K., Wolchok, Jedd D., Carvajal, Richard D., Postow, Michael A.

“…Background. Subtypes of melanoma, such as mucosal, uveal, and acral, are believed to result in worse prognoses than nonacral cutaneous melanoma. After a…”
Get full text

Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment by Callahan, Margaret K, Rampal, Raajit, Harding, James J, Klimek, Virginia M, Chung, Young Rock, Merghoub, Taha, Wolchok, Jedd D, Solit, David B, Rosen, Neal, Abdel-Wahab, Omar, Levine, Ross L, Chapman, Paul B

“…A man with undiagnosed chronic myelomonocytic leukemia began treatment with vemurafenib for BRAF-mutant metastatic melanoma. His white-cell count soared and…”
Get full text

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce by Kluger, Harriet M., Tawbi, Hussein A., Ascierto, Maria L., Bowden, Michaela, Callahan, Margaret K., Cha, Edward, Chen, Helen X., Drake, Charles G., Feltquate, David M., Ferris, Robert L., Gulley, James L., Gupta, Shilpa, Humphrey, Rachel W., LaVallee, Theresa M., Le, Dung T., Hubbard-Lucey, Vanessa M., Papadimitrakopoulou, Vassiliki A., Postow, Michael A., Rubin, Eric H., Sharon, Elad, Taube, Janis M., Topalian, Suzanne L., Zappasodi, Roberta, Sznol, Mario, Sullivan, Ryan J.

“…As the field of cancer immunotherapy continues to advance at a fast pace, treatment approaches and drug development are evolving rapidly to maximize patient…”
Get full text

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma by Shoushtari, Alexander N, Friedman, Claire F, Navid-Azarbaijani, Pedram, Postow, Michael A, Callahan, Margaret K, Momtaz, Parisa, Panageas, Katherine S, Wolchok, Jedd D, Chapman, Paul B

“…Nivolumab plus ipilimumab (nivo + ipi) is a standard treatment of advanced melanoma. Two randomized trials describe high objective response rates by Response…”
Get more information